Lipella Pharmaceuticals Overview
Lipella Pharmaceuticals (LIPO) has a ROE of -172.32%, below the sector sector average of -5.87%.
Get informed when a big investor buys or sells
+ Follow-172.32%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Lipella Pharmaceuticals (LIPO) currently reports a ROE of -172.32%. That is below the sector sector average of -5.87%. Use the charts on this page to explore Lipella Pharmaceuticals's ROE history and peer comparisons.
Lipella Pharmaceuticals's ROE of -172.32% is lower than the its sector sector average of -5.87%. That is roughly 2836.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Lipella Pharmaceuticals's current -172.32% should be judged against industry norms (sector average: -5.87%) and against LIPO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -172.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.87%. From there, open related valuation or income-statement pages for Lipella Pharmaceuticals, and consider following LIPO for alerts when major investors trade the stock.
